Complex Regional Pain Syndrome Market Size Report, 2024-2032

Complex Regional Pain Syndrome (CRPS) Market Size, Share, Growth – By Disease Type, By Treatment, By Route of Administration, By End Use – Growth Forecast, 2024 – 2032  

Report Content

Chapter 1&nbsp;&nbsp;&nbsp;Methodology &amp; Scope

1.1&nbsp;&nbsp;&nbsp; Market scope &amp; definitions

1.2&nbsp;&nbsp;&nbsp; Research design

1.2.1&nbsp;&nbsp;&nbsp; Research approach

1.2.2&nbsp;&nbsp;&nbsp; Data collection methods

1.3&nbsp;&nbsp;&nbsp; Base estimates &amp; calculations

1.3.1&nbsp;&nbsp;&nbsp; Base year calculation

1.3.2&nbsp;&nbsp;&nbsp; Key trends for market estimation

1.4&nbsp;&nbsp;&nbsp; Forecast model

1.5&nbsp;&nbsp;&nbsp; Primary research and validation

1.5.1&nbsp;&nbsp;&nbsp; Primary sources

1.5.2&nbsp;&nbsp;&nbsp; Data mining sources

Chapter 2&nbsp;&nbsp;&nbsp;Executive Summary

2.1&nbsp;&nbsp;&nbsp; Industry 3600 synopsis

Chapter 3&nbsp;&nbsp;&nbsp;Industry Insights

3.1&nbsp;&nbsp;&nbsp; Industry ecosystem analysis

3.2&nbsp;&nbsp;&nbsp; Industry impact forces

3.2.1&nbsp;&nbsp;&nbsp; Growth drivers

3.2.1.1&nbsp;&nbsp;&nbsp; Increasing prevalence of CRPS

3.2.1.2&nbsp;&nbsp;&nbsp; Advancements in pain management therapies

3.2.1.3&nbsp;&nbsp;&nbsp; Rising awareness and diagnosis rates

3.2.2&nbsp;&nbsp;&nbsp; Industry pitfalls &amp; challenges

3.2.2.1&nbsp;&nbsp;&nbsp; High cost of treatment

3.2.2.2&nbsp;&nbsp;&nbsp; Potential side effects of available therapies

3.3&nbsp;&nbsp;&nbsp; Growth potential analysis

3.4&nbsp;&nbsp;&nbsp; Regulatory landscape

3.5&nbsp;&nbsp;&nbsp; Future market trends

3.6&nbsp;&nbsp;&nbsp; Pipeline analysis

3.7&nbsp;&nbsp;&nbsp; Porter&#39;s analysis

3.8&nbsp;&nbsp;&nbsp; PESTEL analysis

Chapter 4&nbsp;&nbsp;&nbsp;Competitive Landscape, 2023

4.1&nbsp;&nbsp;&nbsp; Introduction

4.2&nbsp;&nbsp;&nbsp; Company market share analysis

4.3&nbsp;&nbsp;&nbsp; Company matrix analysis

4.4&nbsp;&nbsp;&nbsp; Competitive analysis of major market players

4.5&nbsp;&nbsp;&nbsp; Competitive positioning matrix

4.6&nbsp;&nbsp;&nbsp; Strategy dashboard

Chapter 5&nbsp;&nbsp;&nbsp;Market Estimates &amp; Forecast, By Disease Type, 2021-2032 ($ Mn)

5.1&nbsp;&nbsp;&nbsp; Key trends

5.2&nbsp;&nbsp;&nbsp; CRPS I

5.3&nbsp;&nbsp;&nbsp; CRPS II

5.4&nbsp;&nbsp;&nbsp; CRPS-NOS

Chapter 6&nbsp;&nbsp;&nbsp;Market Estimates &amp; Forecast, By Treatment, 2021-2032 ($ Mn)

6.1&nbsp;&nbsp;&nbsp; Key trends

6.2&nbsp;&nbsp;&nbsp; Medication

6.2.1&nbsp;&nbsp;&nbsp; Analgesics

6.2.2&nbsp;&nbsp;&nbsp; Antidepressants

6.2.3&nbsp;&nbsp;&nbsp; Corticosteroids

6.2.4&nbsp;&nbsp;&nbsp; Opioids

6.2.5&nbsp;&nbsp;&nbsp; Other medications

6.3&nbsp;&nbsp;&nbsp; Therapy

6.3.1&nbsp;&nbsp;&nbsp; Physical therapy

6.3.2&nbsp;&nbsp;&nbsp; Intrathecal drug pump

6.3.3&nbsp;&nbsp;&nbsp; Spinal cord stimulation

6.3.4&nbsp;&nbsp;&nbsp; Surgical sympathectomy

6.3.5&nbsp;&nbsp;&nbsp; Other therapies

Chapter 7&nbsp;&nbsp;&nbsp;Market Estimates &amp; Forecast, By Route of Administration, 2021-2032 ($ Mn)

7.1&nbsp;&nbsp;&nbsp; Key trends

7.2&nbsp;&nbsp;&nbsp; Oral

7.3&nbsp;&nbsp;&nbsp; Injectable

7.4&nbsp;&nbsp;&nbsp; Other routes of administration

Chapter 8&nbsp;&nbsp;&nbsp;Market Estimates &amp; Forecast, By End Use, 2021-2032 ($ Mn)

8.1&nbsp;&nbsp;&nbsp; Key trends

8.2&nbsp;&nbsp;&nbsp; Hospitals

8.3&nbsp;&nbsp;&nbsp; Clinics

8.4&nbsp;&nbsp;&nbsp; Other end users

Chapter 9&nbsp;&nbsp;&nbsp;Market Estimates &amp; Forecast, By Region, 2021-2032 ($ Mn)

9.1&nbsp;&nbsp;&nbsp; Key trends

9.2&nbsp;&nbsp;&nbsp; North America

9.2.1&nbsp;&nbsp;&nbsp; U.S.

9.2.2&nbsp;&nbsp;&nbsp; Canada

9.3&nbsp;&nbsp;&nbsp; Europe

9.3.1&nbsp;&nbsp;&nbsp; Germany

9.3.2&nbsp;&nbsp;&nbsp; UK

9.3.3&nbsp;&nbsp;&nbsp; France

9.3.4&nbsp;&nbsp;&nbsp; Spain

9.3.5&nbsp;&nbsp;&nbsp; Italy

9.3.6&nbsp;&nbsp;&nbsp; Netherlands

9.4&nbsp;&nbsp;&nbsp; Asia Pacific

9.4.1&nbsp;&nbsp;&nbsp; China

9.4.2&nbsp;&nbsp;&nbsp; Japan

9.4.3&nbsp;&nbsp;&nbsp; India

9.4.4&nbsp;&nbsp;&nbsp; Australia

9.4.5&nbsp;&nbsp;&nbsp; South Korea

9.5&nbsp;&nbsp;&nbsp; Latin America

9.5.1&nbsp;&nbsp;&nbsp; Brazil

9.5.2&nbsp;&nbsp;&nbsp; Mexico

9.5.3&nbsp;&nbsp;&nbsp; Argentina

9.6&nbsp;&nbsp;&nbsp; MEA

9.6.1&nbsp;&nbsp;&nbsp; South Africa

9.6.2&nbsp;&nbsp;&nbsp; Saudi Arabia

9.6.3&nbsp;&nbsp;&nbsp; UAE

Chapter 10&nbsp;&nbsp;&nbsp;Company Profiles

10.1&nbsp;&nbsp;&nbsp; Abbott Laboratories

10.2&nbsp;&nbsp;&nbsp; AbbVie

10.3&nbsp;&nbsp;&nbsp; Averitas Pharma

10.4&nbsp;&nbsp;&nbsp; Boston Scientific

10.5&nbsp;&nbsp;&nbsp; Collegium Pharmaceutical

10.6&nbsp;&nbsp;&nbsp; Eli Lilly and Company

10.7&nbsp;&nbsp;&nbsp; Mallinckrodt Pharmaceuticals

10.8&nbsp;&nbsp;&nbsp; Medtronic

10.9&nbsp;&nbsp;&nbsp; Nevro

10.10&nbsp;&nbsp;&nbsp; Pfizer

10.11&nbsp;&nbsp;&nbsp; Sandoz

10.12&nbsp;&nbsp;&nbsp; Teva Pharmaceutical 
&nbsp;

Complex Regional Pain Syndrome CRPS Market

Get a free sample of this report